Clinical Trial Search

Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With…

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood…

Primary: Safety Tolerability: Number of Ocular and Non-ocular TEAEs — 5; 22; 22 participants

Primary: Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8 — -2.04; -1.71; -2.40 units on a scale — p=0.7669

Primary: Change in Spleen Volume at Week 24 Compared to Baseline — 88.7; -207 cubic centimeter (cm^3)

Primary: Overall Complete Remission Rate — 0; 0; 0; 0 Participants

Primary: Percentage of Subjects Receiving no Opioid Rescue — 30; 27 Participants

Primary: Phase 1: Maximum Tolerated Dose — 25 milligram (mg)

Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004

Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 — 0; 0; 2; 0 Participants

Primary: Time to Early Asthmatic Response (EAR) Upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit (EEU) on Day 8 — 51; NA Minutes — p== 0.0083

Primary: Change From Baseline to Primary Endpoint in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score — -25.00 score on a scale

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutination Inhibition (HAI) Antibodies on Day 22 Against the 2017 Influenza A/H7N9 Vaccine Virus — 22.7; 116.1; 77.7; 190.3…

Primary: Total Sleep Time as Measured by Polysomnography (PSG) — -25.5 Minutes